참고문헌 (108)

1. Ansell S. M. Lesokhin A. M. Borrello I. Halwani A. Scott E. C. Gutierrez M. Schuster S. J. Millenson M. M. Cattry D. Freeman G. J. Rodig S. J. Chapuy B. Ligon A. H. Zhu L. Grosso J. F. Kim S. Y. Timmerman J. M. Shipp M. A. Armand P. 2015 PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma N. Engl. J. Med. 372 311 319 10.1056/NEJMoa1411087 25482239 

   상세보기

2. Aung P. P. Liu Y. C. Ballester L. Y. Robbins P. F. Rosenberg S. A. Lee C. C. 2014 Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma Hum. Pathol. 45 259 267 10.1016/j.humpath.2013.05.029 24290058 

   상세보기

3. Bendell J. C. Fong L. Stein M. N. Beer T. M. Ross A. Gao X. Weitzman A. Austin R. Ganti V. Law C. Lemon B. Wesche H. De Bono J. S. 2020 First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC) J. Clin. Oncol. 38 5552 10.1200/JCO.2020.38.15_suppl.5552 

   상세보기

4. Bielamowicz K. Fousek K. Byrd T. T. Samaha H. Mukherjee M. Aware N. Wu M. F. Orange J. S. Sumazin P. Man T. K. Joseph S. K. Hegde M. Ahmed N. 2018 Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma Neuro-Oncol. 20 506 518 10.1093/neuonc/nox182 29016929 

   상세보기

5. Brentjens R. J. Davila M. L. Riviere I. Park J. Wang X. Cowell L. G. Bartido S. Stefanski J. Taylor C. Olszewska M. Borquez-Ojeda O. Qu J. Wasielewska T. He Q. Bernal Y. Rijo I. V. Hedvat C. Kobos R. Curran K. Steinherz P. Jurcic J. Rosenblat T. Maslak P. Frattini M. Sadelain M. 2013 CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci. Transl. Med. 5 177ra38 10.1126/scitranslmed.3005930 23515080 

   상세보기

6. Brocker T. 2000 Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells Blood 96 1999 2001 10.1182/blood.V96.5.1999 10961908 

   상세보기

7. Brudno J. N. Kochenderfer J. N. 2016 Toxicities of chimeric antigen receptor T cells: recognition and management Blood 127 3321 3330 10.1182/blood-2016-04-703751 27207799 

   상세보기

8. Bubeník J. 2003 Tumour MHC class I downregulation and immunotherapy (review) Oncol. Rep. 10 2005 2008 10.3892/or.10.6.2005 14534734 

   

9. Campbell C. E. Kuriyan N. P. Rackley R. R. Caulfield M. J. Tubbs R. Finke J. Williams B. R. 1998 Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma Int. J. Cancer 78 182 188 10.1002/(SICI)1097-0215(19981005)78:2<182::AID-IJC11>3.0.CO;2-D 9754650 

   상세보기

10. Carpenter R. O. Evbuomwan M. O. Pittaluga S. Rose J. J. Raffeld M. Yang S. Gress R. E. Hakim F. T. Kochenderfer J. N. 2013 B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma Clin. Cancer Res. 19 2048 2060 10.1158/1078-0432.CCR-12-2422 23344265 

    상세보기

11. Carreno B. M. Collins M. 2002 The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses Annu. Rev. Immunol. 20 29 53 10.1146/annurev.immunol.20.091101.091806 11861596 

    상세보기

12. Chandran S. S. Klebanoff C. A. 2019 T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance Immunol. Rev. 290 127 147 10.1111/imr.12772 31355495 

    상세보기

13. Chen D. S. Mellman I. 2013 Oncology meets immunology: the cancer-immunity cycle Immunity 39 1 10 10.1016/j.immuni.2013.07.012 23890059 

    상세보기

14. Chen R. Zinzani P. L. Lee H. J. Armand P. Johnson N. A. Brice P. Radford J. Ribrag V. Molin D. Vassilakopoulos T. P. Tomita A. von Tresckow B. Shipp M. A. Lin J. Kim E. Nahar A. Balakumaran A. Moskowitz C. H. 2019 Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 Blood 134 1144 1153 10.1182/blood.2019000324 31409671 

    상세보기

15. Chow M. T. Möller A. Smyth M. J. 2012 Inflammation and immune surveillance in cancer Semin. Cancer Biol. 22 23 32 10.1016/j.semcancer.2011.12.004 22210181 

    상세보기

16. Cohen E. E. W. Soulieres D. Le Tourneau C. Dinis J. Licitra L. Ahn M. J. Soria A. Machiels J. P. Mach N. Mehra R. Burtness B. Zhang P. Cheng J. Swaby R. F. Harrington K. J. KEYNOTE-040 investigators 2019 Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study Lancet 393 156 167 10.1016/S0140-6736(18)31999-8 30509740 

    상세보기

17. Correnti C. E. Laszlo G. S. de van der Schueren W. Godwin C. D. Bandaranayake A. Busch M. A. Gudgeon C. J. Bates O. M. Olson J. M. Mehlin C. Walter R. B. 2018 Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation Leukemia 32 1239 1243 10.1038/s41375-018-0014-3 29588544 

    상세보기

18. Costa L. J. Wong S. W. Bermúdez A. de la Rubia J. Mateos M. Ocio E. M. Rodríguez-Otero P. San-Miguel J. Li S. Sarmiento R. Lardelli P. Gaudy A. Boss I. Kelly L. M. Burgess M. R. Hege K. Bensinger W. I. 2019 First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial Blood 134 Supplement_1 143 10.1182/blood-2019-122895 

    상세보기

19. D'Angelo S. P. Melchiori L. Merchant M. S. Bernstein D. Glod J. Kaplan R. Grupp S. Tap W. D. Chagin K. Binder G. K. Basu S. Lowther D. E. Wang R. Bath N. Tipping A. Betts G. Ramachandran I. Navenot J. M. Zhang H. Wells D. K. Van Winkle E. Kari G. Trivedi T. Holdich T. Pandite L. Amado R. Mackall C. L. 2018 Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259) T cells in synovial sarcoma Cancer Discov. 8 944 957 10.1158/2159-8290.CD-17-1417 29891538 

    상세보기

20. Daver N. Alotaibi A. S. Bücklein V. Subklewe M. 2021 T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments Leukemia 35 1843 1863 10.1038/s41375-021-01253-x 33953290 

    상세보기

21. Decker W. K. Safdar A. 2009 Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited Cytokine Growth Factor Rev. 20 271 281 10.1016/j.cytogfr.2009.07.004 19656718 

    상세보기

22. D'Ippolito E. Schober K. Nauerth M. Busch D. H. 2019 T cell engineering for adoptive T cell therapy: safety and receptor avidity Cancer Immunol. Immunother. 68 1701 1712 10.1007/s00262-019-02395-9 31542797 

    상세보기

23. Fecci P. E. Ochiai H. Mitchell D. A. Grossi P. M. Sweeney A. E. Archer G. E. Cummings T. Allison J. P. Bigner D. D. Sampson J. H. 2007 Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function Clin. Cancer Res. 13 2158 2167 10.1158/1078-0432.CCR-06-2070 17404100 

    상세보기

24. Ferris R. L. Blumenschein G. Fayette J. Guigay J. Colevas A. D. Licitra L. Harrington K. Kasper S. Vokes E. E. Even C. Worden F. Saba N. F. Iglesias Docampo L. C. Haddad R. Rordorf T. Kiyota N. Tahara M. Monga M. Lynch M. Geese W. J. Kopit J. Shaw J. W. Gillison M. L. 2016 Nivolumab for recurrent squamous-cell carcinoma of the head and neck N. Engl. J. Med. 375 1856 1867 10.1056/NEJMoa1602252 27718784 

    상세보기

25. Garrido F. Aptsiauri N. Doorduijn E. M. Garcia Lora A. M. van Hall T. 2016 The urgent need to recover MHC class I in cancers for effective immunotherapy Curr. Opin. Immunol. 39 44 51 10.1016/j.coi.2015.12.007 26796069 

    상세보기

26. Ghorashian S. Kramer A. M. Onuoha S. Wright G. Bartram J. Richardson R. Albon S. J. Casanovas-Company J. Castro F. Popova B. Villanueva K. Yeung J. Vetharoy W. Guvenel A. Wawrzyniecka P. A. Mekkaoui L. Cheung G. W. Pinner D. Chu J. Lucchini G. Silva J. Ciocarlie O. Lazareva A. Inglott S. Gilmour K. C. Ahsan G. Ferrari M. Manzoor S. Champion K. Brooks T. Lopes A. Hackshaw A. Farzaneh F. Chiesa R. Rao K. Bonney D. Samarasinghe S. Goulden N. Vora A. Veys P. Hough R. Wynn R. Pule M. A. Amrolia P. J. 2019 Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR Nat. Med. 25 1408 1414 10.1038/s41591-019-0549-5 31477906 

    상세보기

27. Gilboa E. 1999 The makings of a tumor rejection antigen Immunity 11 263 270 10.1016/S1074-7613(00)80101-6 10514004 

    상세보기

28. Gong J. Chehrazi-Raffle A. Reddi S. Salgia R. 2018 Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations J. Immunother. Cancer 6 8 10.1186/s40425-018-0316-z 29357948 

    상세보기

29. Green E. W. Bunse L. Bozza M. Sanghvi K. Platten M. 2019 TCR validation toward gene therapy for cancer Methods Enzymol. 629 419 441 10.1016/bs.mie.2019.10.010 31727252 

    

30. Grosso J. F. Jure-Kunkel M. N. 2013 CTLA-4 blockade in tumor models: an overview of preclinical and translational research Cancer Immun. 13 5 23390376 

31. Grupp S. A. Kalos M. Barrett D. Aplenc R. Porter D. L. Rheingold S. R. Teachey D. T. Chew A. Hauck B. Wright J. F. Milone M. C. Levine B. L. June C. H. 2013 Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N. Engl. J. Med. 368 1509 1518 10.1056/NEJMoa1215134 23527958 

    상세보기

32. Halliday G. M. Patel A. Hunt M. J. Tefany F. J. Barnetson R. S. 1995 Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells World J. Surg. 19 352 358 10.1007/BF00299157 7638987 

    상세보기

33. Hargadon K. M. Johnson C. E. Williams C. J. 2018 Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors Int. Immunopharmacol. 62 29 39 10.1016/j.intimp.2018.06.001 29990692 

    상세보기

34. Harrison S. J. Minnema M. C. Lee H. C. Spencer A. Kapoor P. Madduri D. Larsen J. Ailawadhi S. Kaufman J. L. Raab M. S. Hari P. Iida S. Vij R. Davies F. E. Lesley R. Upreti V. V. Yang Z. Sharma A. Minella A. Lentzsch S. 2020 A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE® (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM) Blood 136 28 29 10.1182/blood-2020-134063 

    상세보기

35. Herbst R. S. Baas P. Kim D. W. Felip E. Perez-Gracia J. L. Han J. Y. Molina J. Kim J. H. Arvis C. D. Ahn M. J. Majem M. Fidler M. J. de Castro G. Garrido M. Lubiniecki G. M. Shentu Y. Im E. Dolled-Filhart M. Garon E. B. 2016 Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 387 1540 1550 10.1016/S0140-6736(15)01281-7 26712084 

    상세보기

36. Hilal T. Prasad V. 2018 Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission Nat. Rev. Clin. Oncol. 15 727 728 10.1038/s41571-018-0087-y 30181661 

    상세보기

37. Hirano F. Kaneko K. Tamura H. Dong H. Wang S. Ichikawa M. Rietz C. Flies D. B. Lau J. S. Zhu G. Tamada K. Chen L. 2005 Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res. 65 1089 1096 10.1158/0008-5472.1089.65.3 15705911 

    상세보기

38. Hodi F. S. Mihm M. C. Soiffer R. J. Haluska F. G. Butler M. Seiden M. V. Davis T. Henry-Spires R. MacRae S. Willman A. Padera R. Jaklitsch M. T. Shankar S. Chen T. C. Korman A. Allison J. P. Dranoff G. 2003 Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc. Natl. Acad. Sci. U.S.A. 100 4712 4717 10.1073/pnas.0830997100 12682289 

    상세보기

39. Hodi F. S. O'Day S. J. McDermott D. F. Weber R. W. Sosman J. A. Haanen J. B. Gonzalez R. Robert C. Schadendorf D. Hassel J. C. Akerley W. van den Eertwegh A. J. Lutzky J. Lorigan P. Vaubel J. M. Linette G. P. Hogg D. Ottensmeier C. H. Lebbe C. Peschel C. Quirt I. Clark J. I. Wolchok J. D. Weber J. S. Tian J. Yellin M. J. Nichol G. M. Hoos A. Urba W. J. 2010 Improved survival with ipilimumab in patients with metastatic melanoma. N . Engl . J . Me d. 363 711 723 10.1056/NEJMoa1003466 20525992 

    상세보기

40. Hoffmann M. M. Slansky J. E. 2020 T-cell receptor affinity in the age of cancer immunotherapy Mol. Carcinog. 59 862 870 10.1002/mc.23212 32386086 

    상세보기

41. Huang J. Brameshuber M. Zeng X. Xie J. Li Q. J. Chien Y. H. Valitutti S. Davis M. M. 2013 A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4(+) T cells Immunity 39 846 857 10.1016/j.immuni.2013.08.036 24120362 

    상세보기

42. Huang L. Q. Brasseur F. Serrano A. De Plaen E. van der Bruggen P. Boon T. Van Pel A. 1999 Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma J. Immunol. 162 6849 6854 10352307 

    상세보기

43. Hummel H. D. Kufer P. Grüllich C. Seggewiss-Bernhardt R. Deschler-Baier B. Chatterjee M. Goebeler M. E. Miller K. de Santis M. Loidl W. Dittrich C. Buck A. Lapa C. Thurner A. Wittemer-Rump S. Koca G. Boix O. Döcke W. D. Finnern R. Kusi H. Ajavon-Hartmann A. Stienen S. Sayehli C. M. Polat B. Bargou R. C. 2021 Pasotuxizumab, a BiTE(®) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings Immunotherapy 13 125 141 10.2217/imt-2020-0256 33172323 

    상세보기

44. Hung C. F. Xu X. Li L. Ma Y. Jin Q. Viley A. Allen C. Natarajan P. Shivakumar R. Peshwa M. V. Emens L. A. 2018 Development of anti-human mesothelin-targeted chimeric antigen receptor messenger RNA-transfected peripheral blood lymphocytes for ovarian cancer therapy Hum. Gene Ther. 29 614 625 10.1089/hum.2017.080 29334771 

    상세보기

45. Imai C. Mihara K. Andreansky M. Nicholson I. C. Pui C. H. Geiger T. L. Campana D. 2004 Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia Leukemia 18 676 684 10.1038/sj.leu.2403302 14961035 

    상세보기

46. Ishiguro T. Sano Y. Komatsu S. I. Kamata-Sakurai M. Kaneko A. Kinoshita Y. Shiraiwa H. Azuma Y. Tsunenari T. Kayukawa Y. Sonobe Y. Ono N. Sakata K. Fujii T. Miyazaki Y. Noguchi M. Endo M. Harada A. Frings W. Fujii E. Nanba E. Narita A. Sakamoto A. Wakabayashi T. Konishi H. Segawa H. Igawa T. Tsushima T. Mutoh H. Nishito Y. Takahashi M. Stewart L. ElGabry E. Kawabe Y. Ishigai M. Chiba S. Aoki M. Hattori K. Nezu J. 2017 An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors Sci. Transl. Med. 9 eaal4291 10.1126/scitranslmed.aal4291 28978751 

    상세보기

47. Iwai Y. Ishida M. Tanaka Y. Okazaki T. Honjo T. Minato N. 2002 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc. Natl. Acad. Sci. U.S.A. 99 12293 12297 10.1073/pnas.192461099 12218188 

    상세보기

48. Karapetyan A. R. Chaipan C. Winkelbach K. Wimberger S. Jeong J. S. Joshi B. Stein R. B. Underwood D. Castle J. C. van Dijk M. Seibert V. 2019 TCR fingerprinting and off-target peptide identification Front. Immunol. 10 2501 10.3389/fimmu.2019.02501 31695703 

    상세보기

49. Klinger M. Benjamin J. Kischel R. Stienen S. Zugmaier G. 2016 Harnessing T cells to fight cancer with BiTE(R) antibody constructs--past developments and future directions Immunol. Rev. 270 193 208 10.1111/imr.12393 26864113 

    상세보기

50. Klinger M. Zugmaier G. Nagele V. Goebeler M. E. Brandl C. Stelljes M. Lassmann H. von Stackelberg A. Bargou R. C. Kufer P. 2020 Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events Cancer Res. 80 91 101 10.1158/0008-5472.CAN-19-1131 31662326 

    상세보기

51. Kontermann R. E. Brinkmann U. 2015 Bispecific antibodies Drug Discov. Today 20 838 847 10.1016/j.drudis.2015.02.008 25728220 

    상세보기

52. Kumar V. Chaudhary N. Garg M. Floudas C. S. Soni P. Chandra A. B. 2017 Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy Front. Pharmacol. 8 49 10.3389/fphar.2017.00049 28228726 

    상세보기

53. Kuwana Y. Asakura Y. Utsunomiya N. Nakanishi M. Arata Y. Itoh S. Nagase F. Kurosawa Y. 1987 Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions Biochem. Biophys. Res. Commun. 149 960 968 10.1016/0006-291X(87)90502-X 3122749 

    상세보기

54. Leach D. R. Krummel M. F. Allison J. P. 1996 Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1734 1736 10.1126/science.271.5256.1734 8596936 

    상세보기

55. Lee L. Wang R. F. Wang X. Mixon A. Johnson B. E. Rosenberg S. A. Schrump D. S. 1999 NY-ESO-1 may be a potential target for lung cancer immunotherapy Cancer J. Sci. Am. 5 20 25 10188057 

56. Liu Y. Zheng P. 2020 Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy Trends Pharmacol. Sci. 41 4 12 10.1016/j.tips.2019.11.003 31836191 

    상세보기

57. Loffler A. Kufer P. Lutterbuse R. Zettl F. Daniel P. T. Schwenkenbecher J. M. Riethmuller G. Dorken B. Bargou R. C. 2000 A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes Blood 95 2098 2103 10.1182/blood.V95.6.2098 10706880 

    상세보기

58. Lorenczewski G. Friedrich M. Kischel R. Dahlhoff C. Anlahr J. Balazs M. Rock D. Boyle M. C. Goldstein R. Coxon A. Chapman-Arvedson T. 2017 Generation of a half-life extended anti-CD19 BiTE® antibody construct compatible with once-weekly dosing for treatment of CD19-positive malignancies Blood 130 2815 

59. Lu Y. Parker L. Lu T. Zheng Z. Yao X. Robbins P. F. van der Bruggen P. Klebanoff C. A. Hinrichs C. S. Goff S. Sherry R. Kammula U. Yang J. C. Rosenberg S. A. 2015 A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers. J. Immunother Cancer 3 P158 10.1186/2051-1426-3-S2-P158 

    상세보기

60. Lynn R. C. Weber E. W. Sotillo E. Gennert D. Xu P. Good Z. Anbunathan H. Lattin J. Jones R. Tieu V. Nagaraja S. Granja J. de Bourcy C. F. A. Majzner R. Satpathy A. T. Quake S. R. Monje M. Chang H. Y. Mackall C. L. 2019 c-Jun overexpression in CAR T cells induces exhaustion resistance Nature 576 293 300 10.1038/s41586-019-1805-z 31802004 

    상세보기

61. Maher J. Brentjens R. J. Gunset G. Riviere I. Sadelain M. 2002 Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor Nat. Biotechnol. 20 70 75 10.1038/nbt0102-70 11753365 

    상세보기

62. Majzner R. G. Theruvath J. L. Nellan A. Heitzeneder S. Cui Y. Mount C. W. Rietberg S. P. Linde M. H. Xu P. Rota C. Sotillo E. Labanieh L. Lee D. W. Orentas R. J. Dimitrov D. S. Zhu Z. Croix B. S. Delaidelli A. Sekunova A. Bonvini E. Mitra S. S. Quezado M. M. Majeti R. Monje M. Sorensen P. H. B. Maris J. M. Mackall C. L. 2019 CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors Clin. Cancer Res. 25 2560 2574 10.1158/1078-0432.CCR-18-0432 30655315 

    상세보기

63. Malik-Chaudhry H. K. Prabhakar K. Ugamraj H. S. Boudreau A. A. Buelow B. Dang K. Davison L. M. Harris K. E. Jorgensen B. Ogana H. Pham D. Schellenberger U. Van Schooten W. Buelow R. Iyer S. Trinklein N. D. Rangaswamy U. S. 2021 TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL mAbs 13 1890411 10.1080/19420862.2021.1890411 33818299 

    상세보기

64. Mangsbo S. M. Sandin L. C. Anger K. Korman A. J. Loskog A. Totterman T. H. 2010 Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy J. Immunother. 33 225 235 10.1097/CJI.0b013e3181c01fcb 20445343 

    상세보기

65. Mhawech-Fauceglia P. Zhang S. Terracciano L. Sauter G. Chadhuri A. Herrmann F. R. Penetrante R. 2007 Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutipletumour tissue microarray technique Histopathology 50 472 483 10.1111/j.1365-2559.2007.02635.x 17448023 

    상세보기

66. Miyoshi Y. Ando A. Egawa C. Taguchi T. Tamaki Y. Tamaki H. Sugiyama H. Noguchi S. 2002 High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients Clin. Cancer Res. 8 1167 1171 12006533 

    상세보기

67. Motzer R. J. Tannir N. M. McDermott D. F. Aren Frontera O. Melichar B. Choueiri T. K. Plimack E. R. Barthelemy P. Porta C. George S. Powles T. Donskov F. Neiman V. Kollmannsberger C. K. Salman P. Gurney H. Hawkins R. Ravaud A. Grimm M. O. Bracarda S. Barrios C. H. Tomita Y. Castellano D. Rini B. I. Chen A. C. Mekan S. McHenry M. B. Wind-Rotolo M. Doan J. Sharma P. Hammers H. J. Escudier B. CheckMate 214 Investigators 2018 Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma N. Engl. J. Med. 378 1277 1290 10.1056/NEJMoa1712126 29562145 

    상세보기

68. Mullard A. 2021 FDA approves first BCMA-targeted CAR-T cell therapy Nat. Rev. Drug Discov. 20 332 10.1038/d41573-021-00063-1 33790473 

    상세보기

69. Nair-Gupta P. Diem M. Reeves D. Wang W. Schulingkamp R. Sproesser K. Mattson B. Heidrich B. Mendonca M. Joseph J. Sendecki J. Foulk B. Chu G. Fink D. Jiao Q. Wu S. J. Packman K. Elsayed Y. Attar R. Gaudet F. 2020 A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia Blood Adv. 4 906 919 10.1182/bloodadvances.2019001188 32150609 

    상세보기

70. Neelapu S. S. Tummala S. Kebriaei P. Wierda W. Locke F. L. Lin Y. Jain N. Daver N. Gulbis A. M. Adkins S. Rezvani K. Hwu P. Shpall E. J. 2018 Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' Nat. Rev. Clin. Oncol. 15 218 10.1038/nrclinonc.2018.20 29434334 

    상세보기

71. Ott P. A. Hu Z. Keskin D. B. Shukla S. A. Sun J. Bozym D. J. Zhang W. Luoma A. Giobbie-Hurder A. Peter L. Chen C. Olive O. Carter T. A. Li S. Lieb D. J. Eisenhaure T. Gjini E. Stevens J. Lane W. J. Javeri I. Nellaiappan K. Salazar A. M. Daley H. Seaman M. Buchbinder E. I. Yoon C. H. Harden M. Lennon N. Gabriel S. Rodig S. J. Barouch D. H. Aster J. C. Getz G. Wucherpfennig K. Neuberg D. Ritz J. Lander E. S. Fritsch E. F. Hacohen N. Wu C. J. 2017 An immunogenic personal neoantigen vaccine for patients with melanoma Nature 547 217 221 10.1038/nature22991 28678778 

    상세보기

72. Palmer D. C. Guittard G. C. Franco Z. Crompton J. G. Eil R. L. Patel S. J. Ji Y. Van Panhuys N. Klebanoff C. A. Sukumar M. Clever D. Chichura A. Roychoudhuri R. Varma R. Wang E. Gattinoni L. Marincola F. M. Balagopalan L. Samelson L. E. Restifo N. P. 2015 Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance J. Exp. Med. 212 2095 2113 10.1084/jem.20150304 26527801 

    상세보기

73. Porter D. L. Kalos M. Zheng Z. Levine B. June C. 2011a Chimeric antigen receptor therapy for B-cell malignancies J. Cancer 2 331 332 10.7150/jca.2.331 21716851 

    상세보기

74. Porter D. L. Levine B. L. Kalos M. Bagg A. June C. H. 2011b Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl J. Med. 365 725 733 10.1056/NEJMoa1103849 21830940 

    상세보기

75. Ramachandran I. Lowther D. E. Dryer-Minnerly R. Wang R. Fayngerts S. Nunez D. Betts G. Bath N. Tipping A. J. Melchiori L. Navenot J. M. Glod J. Mackall C. L. D'Angelo S. P. Araujo D. M. Chow W. A. Demetri G. D. Druta M. Van Tine B. A. Grupp S. A. Abdul Razak A. R. Wilky B. Iyengar M. Trivedi T. Winkle E. V. Chagin K. Amado R. Binder G. K. Basu S. 2019 Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma J. Immunother. Cancer 7 276 10.1186/s40425-019-0762-2 31651363 

    상세보기

76. Rapoport A. P. Stadtmauer E. A. Binder-Scholl G. K. Goloubeva O. Vogl D. T. Lacey S. F. Badros A. Z. Garfall A. Weiss B. Finklestein J. Kulikovskaya I. Sinha S. K. Kronsberg S. Gupta M. Bond S. Melchiori L. Brewer J. E. Bennett A. D. Gerry A. B. Pumphrey N. J. Williams D. Tayton-Martin H. K. Ribeiro L. Holdich T. Yanovich S. Hardy N. Yared J. Kerr N. Philip S. Westphal S. Siegel D. L. Levine B. L. Jakobsen B. K. Kalos M. June C. H. 2015 NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma Nat. Med. 21 914 921 10.1038/nm.3910 26193344 

    상세보기

77. Reck M. Rodriguez-Abreu D. Robinson A. G. Hui R. Csoszi T. Fulop A. Gottfried M. Peled N. Tafreshi A. Cuffe S. O'Brien M. Rao S. Hotta K. Leiby M. A. Lubiniecki G. M. Shentu Y. Rangwala R. Brahmer J. R. KEYNOTE-024 Investigators 2016 Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer N. Engl. J. Med. 375 1823 1833 10.1056/NEJMoa1606774 27718847 

    상세보기

78. Riley R. S. June C. H. Langer R. Mitchell M. J. 2019 Delivery technologies for cancer immunotherapy Nat. Rev. Drug Discov. 18 175 196 10.1038/s41573-018-0006-z 30622344 

    상세보기

79. Robbins P. F. Kassim S. H. Tran T. L. Crystal J. S. Morgan R. A. Feldman S. A. Yang J. C. Dudley M. E. Wunderlich J. R. Sherry R. M. Kammula U. S. Hughes M. S. Restifo N. P. Raffeld M. Lee C. C. Li Y. F. El-Gamil M. Rosenberg S. A. 2015 A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response Clin. Cancer Res. 21 1019 1027 10.1158/1078-0432.CCR-14-2708 25538264 

    상세보기

80. Rosenberg S. A. Packard B. S. Aebersold P. M. Solomon D. Topalian S. L. Toy S. T. Simon P. Lotze M. T. Yang J. C. Seipp C. A. 1988 Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report N. Engl. J. Med. 319 1676 1680 10.1056/NEJM198812223192527 3264384 

    상세보기

81. Rosenberg S. A. Yang J. C. Sherry R. M. Kammula U. S. Hughes M. S. Phan G. Q. Citrin D. E. Restifo N. P. Robbins P. F. Wunderlich J. R. Morton K. E. Laurencot C. M. Steinberg S. M. White D. E. Dudley M. E. 2011 Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin. Cancer Res. 17 4550 4557 10.1158/1078-0432.CCR-11-0116 21498393 

    상세보기

82. Rosenthal M. A. Balana C. van Linde M. E. Sayehli C. Fiedler W. M. Wermke M. Massard C. Mellinghoff I. K. Khasraw M. Ang A. Rasmussen E. Kast J. Stienen S. Cloughesy T. F. 2019 ATIM-49 (LTBK-01). AMG 596, a novel anti-EGFRvIII bispecific T cell engager (BITE(®)) molecule for the treatment of glioblastoma (GBM): planned interim analysis in recurrent GBM (RGBM) Neuro-Oncol 21 vi283 10.1093/neuonc/noz219.1195 

    상세보기

83. Sahin U. Derhovanessian E. Miller M. Kloke B. P. Simon P. Lower M. Bukur V. Tadmor A. D. Luxemburger U. Schrors B. Omokoko T. Vormehr M. Albrecht C. Paruzynski A. Kuhn A. N. Buck J. Heesch S. Schreeb K. H. Muller F. Ortseifer I. Vogler I. Godehardt E. Attig S. Rae R. Breitkreuz A. Tolliver C. Suchan M. Martic G. Hohberger A. Sorn P. Diekmann J. Ciesla J. Waksmann O. Brück A. K. Witt M. Zillgen M. Rothermel A. Kasemann B. Langer D. Bolte S. Diken M. Kreiter S. Nemecek R. Gebhardt C. Grabbe S. Höller C. Utikal J. Huber C. Loquai C. Tureci O. 2017 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer Nature 547 222 226 10.1038/nature23003 28678784 

    상세보기

84. Schadendorf D. Hodi F. S. Robert C. Weber J. S. Margolin K. Hamid O. Patt D. Chen T. T. Berman D. M. Wolchok J. D. 2015 Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma J. Clin. Oncol. 33 1889 1894 10.1200/JCO.2014.56.2736 25667295 

    상세보기

85. Schlothauer T. Herter S. Koller C. F. Grau-Richards S. Steinhart V. Spick C. Kubbies M. Klein C. Umana P. Mossner E. 2016 Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions Protein Eng. Des. Sel. 29 457 466 10.1093/protein/gzw040 27578889 

    상세보기

86. Schultz-Thater E. Piscuoglio S. Iezzi G. Le Magnen C. Zajac P. Carafa V. Terracciano L. Tornillo L. Spagnoli G. C. 2011 MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies Int. J. Cancer 129 1137 1148 10.1002/ijc.25777 21710496 

    상세보기

87. Shimabukuro-Vornhagen A. Godel P. Subklewe M. Stemmler H. J. Schlosser H. A. Schlaak M. Kochanek M. Boll B. von Bergwelt-Baildon M. S. 2018 Cytokine release syndrome J. Immunother. Cancer 6 56 10.1186/s40425-018-0343-9 29907163 

    상세보기

88. Song S. Han M. Zhang H. Wang Y. Jiang H. 2013 Full screening and accurate subtyping of HLA-A*02 alleles through group-specific amplification and mono-allelic sequencing Cell. Mol. Immunol. 10 490 496 10.1038/cmi.2013.33 23954948 

    상세보기

89. Stein A. S. Schiller G. Benjamin R. Jia C. Zhang A. Zhu M. Zimmerman Z. Topp M. S. 2019 Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors Ann. Hematol. 98 159 167 10.1007/s00277-018-3497-0 30238148 

    상세보기

90. Strome S. E. Dong H. Tamura H. Voss S. G. Flies D. B. Tamada K. Salomao D. Cheville J. Hirano F. Lin W. Kasperbauer J. L. Ballman K. V. Chen L. 2003 B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Res. 63 6501 6505 14559843 

    상세보기

91. Sugita Y. Wada H. Fujita S. Nakata T. Sato S. Noguchi Y. Jungbluth A. A. Yamaguchi M. Chen Y. T. Stockert E. Gnjatic S. Williamson B. Scanlan M. J. Ono T. Sakita I. Yasui M. Miyoshi Y. Tamaki Y. Matsuura N. Noguchi S. Old L. J. Nakayama E. Monden M. 2004 NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors Cancer Res. 64 2199 2204 10.1158/0008-5472.CAN-03-3070 15026363 

    상세보기

92. Tan M. P. Gerry A. B. Brewer J. E. Melchiori L. Bridgeman J. S. Bennett A. D. Pumphrey N. J. Jakobsen B. K. Price D. A. Ladell K. Sewell A. K. 2015 T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells Clin. Exp. Immunol. 180 255 270 10.1111/cei.12570 25496365 

    상세보기

93. Thakur A. Huang M. Lum L. G. 2018 Bispecific antibody based therapeutics: strengths and challenges Blood Rev. 32 339 347 10.1016/j.blre.2018.02.004 29482895 

    상세보기

94. Topp M. S. Duell J. Zugmaier G. Attal M. Moreau P. Langer C. Kronke J. Facon T. Salnikov A. V. Lesley R. Beutner K. Kalabus J. Rasmussen E. Riemann K. Minella A. C. Munzert G. Einsele H. 2020 Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma J. Clin. Oncol. 38 775 783 10.1200/JCO.19.02657 31895611 

    상세보기

95. Turley S. J. Cremasco V. Astarita J. L. 2015 Immunological hallmarks of stromal cells in the tumour microenvironment Nat. Rev. Immunol. 15 669 682 10.1038/nri3902 26471778 

    상세보기

96. Twyman-Saint Victor C. Rech A. J. Maity A. Rengan R. Pauken K. E. Stelekati E. Benci J. L. Xu B. Dada H. Odorizzi P. M. Herati R. S. Mansfield K. D. Patsch D. Amaravadi R. K. Schuchter L. M. Ishwaran H. Mick R. Pryma D. A. Xu X. Feldman M. D. Gangadhar T. C. Hahn S. M. Wherry E. J. Vonderheide R. H. Minn A. J. 2015 Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer Nature 520 373 377 10.1038/nature14292 25754329 

    상세보기

97. Viardot A. Goebeler M. E. Hess G. Neumann S. Pfreundschuh M. Adrian N. Zettl F. Libicher M. Sayehli C. Stieglmaier J. Zhang A. Nagorsen D. Bargou R. C. 2016 Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma Blood 127 1410 1416 10.1182/blood-2015-06-651380 26755709 

    상세보기

98. Wang T. T. Ravetch J. V. 2019 Functional diversification of IgGs through Fc glycosylation J. Clin. Invest. 129 3492 3498 10.1172/JCI130029 31478910 

    상세보기

99. Weber J. Mandala M. Del Vecchio M. Gogas H. J. Arance A. M. Cowey C. L. Dalle S. Schenker M. Chiarion-Sileni V. Marquez-Rodas I. Grob J. J. Butler M. O. Middleton M. R. Maio M. Atkinson V. Queirolo P. Gonzalez R. Kudchadkar R. R. Smylie M. Meyer N. Mortier L. Atkins M. B. Long G. V. Bhatia S. Lebbé C. Rutkowski P. Yokota K. Yamazaki N. Kim T. M. de Pril V. Sabater J. Qureshi A. Larkin J. Ascierto P. A. CheckMate 238 Collaborators 2017 Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma N. Engl. J. Med. 377 1824 1835 10.1056/NEJMoa1709030 28891423 

    상세보기

100. Wilkie S. Burbridge S. E. Chiapero-Stanke L. Pereira A. C. Cleary S. van der Stegen S. J. Spicer J. F. Davies D. M. Maher J. 2010 Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4 J. Biol. Chem. 285 25538 25544 10.1074/jbc.M110.127951 20562098 

     상세보기

101. Wing K. Onishi Y. Prieto-Martin P. Yamaguchi T. Miyara M. Fehervari Z. Nomura T. Sakaguchi S. 2008 CTLA-4 control over Foxp3+ regulatory T cell function Science 322 271 275 10.1126/science.1160062 18845758 

     상세보기

102. Wolchok J. D. Chiarion-Sileni V. Gonzalez R. Rutkowski P. Grob J. J. Cowey C. L. Lao C. D. Wagstaff J. Schadendorf D. Ferrucci P. F. Smylie M. Dummer R. Hill A. Hogg D. Haanen J. Carlino M. S. Bechter O. Maio M. Marquez-Rodas I. Guidoboni M. McArthur G. Lebbé C. Ascierto P. A. Long G. V. Cebon J. Sosman J. Postow M. A. Callahan M. K. Walker D. Rollin L. Bhore R. Hodi F. S. Larkin J. 2017 Overall survival with combined nivolumab and ipilimumab in advanced melanoma N. Engl. J. Med. 377 1345 1356 10.1056/NEJMoa1709684 28889792 

     상세보기

103. Wu J. Fu J. Zhang M. Liu D. 2015 Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia J. Hematol. Oncol. 8 104 10.1186/s13045-015-0195-4 26337639 

     상세보기

104. Yang Y. F. Zou J. P. Mu J. Wijesuriya R. Ono S. Walunas T. Bluestone J. Fujiwara H. Hamaoka T. 1997 Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages Cancer Res. 57 4036 4041 9307290 

     상세보기

105. Zacharakis N. Chinnasamy H. Black M. Xu H. Lu Y. C. Zheng Z. Pasetto A. Langhan M. Shelton T. Prickett T. Gartner J. Jia L. Trebska-McGowan K. Somerville R. P. Robbins P. F. Rosenberg S. A. Goff S. L. Feldman S. A. 2018 Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer Nat. Med. 24 724 730 10.1038/s41591-018-0040-8 29867227 

     상세보기

106. Zehn D. Lee S. Y. Bevan M. J. 2009 Complete but curtailed T-cell response to very low-affinity antigen Nature 458 211 214 10.1038/nature07657 19182777 

     상세보기

107. Zhang Y. Du X. Liu M. Tang F. Zhang P. Ai C. Fields J. K. Sundberg E. J. Latinovic O. S. Devenport M. Zheng P. Liu Y. 2019 Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy Cell Res. 29 609 627 10.1038/s41422-019-0184-1 31267017 

     상세보기

108. Zhao J. Zhao J. Perlman S. 2012 Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-gamma, IL-2 and IL-2R PLoS ONE 7 e46241 10.1371/journal.pone.0046241 23029447 

     상세보기